The project is agreed as a joint collaboration among IBAR and ATOMKI, UD and IFIN-HH is a cost free participant. There are two main directions envisaged by the proposed project: receptors mapping and therapy, using an affibody against HER2 receptor, combined with an adequate radioisotope. In this respect, the specific objectives are: a) expression and purification of affibodies; b) establish labeling procedures; c) ex vivo and/or in vivo testing of optimal compounds.
Our collaboration will eventually set the premises for further development of biomarkers labeled with 64Cu/52Mn aimed for PET imaging in our institutions and usage of therapy with 64Cu/52 emiters in situ, at the level of affected areas in various solid tumor cancers and micrometastases. The expected results will be the basis of the further research work in Hungary according to the bimodal diagnostic such the PET-MRI imaging. The 52Mn as PET radioisotope, the Mn2+ as a powerful paramagnetic ion for MRI will play a main role in the near future.